首页|国际细胞治疗临床研究发展现状及监管政策研究

国际细胞治疗临床研究发展现状及监管政策研究

扫码查看
细胞治疗作为生物医学领域的前沿热点,其快速的创新发展不仅关乎公众健康,更深刻影响国家的生物安全.欧美、日本等发达国家已将此提升至国家战略高度,并构建了完善的药品监管体系以巩固其在细胞治疗领域的领先地位.本文通过统计分析与研究,全面梳理了全球主要国家及地区和我国的细胞治疗临床研究现状,追踪各国监管体系的演变,并系统整理了关键的规范指南.基于此,初步提出了针对我国细胞治疗产品与技术双轨制监管体系的建议,旨在为相关机构、企业及从业人员提供有价值的参考.
Study on the International Development of Clinical Research and Regulatory Policies on Cell Therapy
Cell therapy,as a cutting-edge hotspot in the biomedical field,its rapid pace of innovation and development not only bears significance for public health but also profoundly impacts national biosafety.Developed countries such as Europe,the United States,and Japan have elevated this to the level of national strategy and established comprehensive drug regulatory systems to consolidate their leading positions in the field of cell therapy.Through rigorous statistical analysis and research,this article comprehensively reviews the current status of cell therapy clinical research in major countries and regions worldwide,tracks the evolution of regulatory systems in Europe,the United States,Japan,and China,and systematically compiles key normative guidelines.Based on these findings,preliminary suggestions for a dual-track regulatory system for cell therapy products and technologies in China are proposed,aiming to provide valuable references for relevant agencies,enterprises,and practitioners.

Cell therapyClinical researchDrug regulatory scienceTechnological innovation

朱凤昌、叶潇、崇小萌、江翊国

展开 >

中国药学会,北京 100050

中国食品药品检定研究院,北京 100050

南京医科大学附属苏州科技城医院,江苏苏州 215153

细胞治疗 临床研究 药品监管科学 技术创新

2024

中国药物评价
国家食品药品监督管理局信息中心

中国药物评价

影响因子:1.09
ISSN:2095-3593
年,卷(期):2024.41(4)